Funding profile · Cardiac remote monitoring

Bodyport

$15.8 million reported raised, all of it on or before an August 2020 Series A, and not one Form D on file with the SEC. The gap between what the press reported and what the filing record holds is the whole story here.

$11.2MSeries A, August 2020, led by Boehringer Ingelheim Venture Fund
$15.8MTotal raised to date, company and investor reported (Aug 2020)
$4.6MPrior capital before the Series A, per MassDevice
0Form D filings and EDGAR documents mentioning Bodyport

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2015 Y Combinator, Summer 2015 Not disclosed Y Combinator YC data
2015 to 2020 Angel, then seed $4.6M in aggregate Initialized Capital, Playground Global Independent
Aug 2020 Series A $11.2M Boehringer Ingelheim Venture Fund (lead), Playground Global, Initialized Capital Company release
Aug 2020 Series A, investor account Same round Initialized names Kapor Capital in place of itself as a co-investor Accounts differ
After 2020 No round announced Not disclosed Terumo Medical and Rock Health appear in the 2025 and 2026 investor list but not in the 2020 release Company-stated
To date Reported total $15.8M Unchanged in every public account since August 2020 Independent

What the filings show

SEC EDGAR · full text search · run Sep 22, 2026

Query
Phrase “Bodyport” across all form types
Documents
0
Form D
None
Vehicles
No SPV or fund filing names the company

SEC EDGAR · company search · run Sep 22, 2026

Query
Company name Bodyport, form type D
Result
No matching companies
CIK
None assigned
Federal grants
No NIH or NSF award on record

Reading the filings

  1. No Form D is not the same as no money.Rule 506 offerings require a Form D within 15 days of first sale. Offerings made under Section 4(a)(2) do not. Two independent outlets and the lead investor put at least $15.8 million into this company, and EDGAR holds nothing at all, so the capital moved outside Regulation D.
  2. The arithmetic on the reported total is clean.$15.8M total minus the $11.2M Series A leaves $4.6M, which is exactly the prior capital MassDevice attributed to Playground Global, Initialized and others on the day the round closed. The two numbers were reported by different outlets and agree.
  3. The total has not moved in six years.Every public figure still reads $15.8 million, and company boilerplate from October 2025 through January 2026 names investors but no amount. For a company running two trials and shipping cellular hardware, that points to undisclosed financing.
  4. Two names joined the investor list without a round.The 2020 release lists Boehringer Ingelheim Venture Fund, Playground Global and Initialized. The 2025 and 2026 boilerplate reads “backed by top-tier investors including Boehringer Ingelheim Venture Fund, Terumo Medical, Initialized Capital, Playground Global, Rock Health, and Y Combinator.” Terumo Medical, a device manufacturer, is new. No amount, no date, no filing.
  5. The money is strategic, not financial.The lead is a pharmaceutical company venture arm whose stated interest is whether the technology “could potentially complement pharmaceutical therapies for patients with various cardiovascular diseases.” Add a device maker on the list and the cap table looks built for a partnership or an acquisition rather than an IPO.
  6. The board grew faster than the disclosed capital.Three investors took seats in 2020. By June 2022 it held six: both founders, the new CEO, Garry Tan, Stefan Pflanz for Boehringer in place of Debbie Lin, and chair Phyllis Whiteley, with Jim Pursley added that month.

Commercial signals

Signal Detail Source type
Regulatory 510(k) K211585, cleared Jul 29, 2022, product code DSB, class II. The Congestion Index is sold as clinical decision support and is not itself cleared. No second 510(k). Public record
Operating status FDA establishment registration 3020885267 active, 2026 expiry year, 120 2nd St., San Francisco. Public record
Clinical spend Two sponsored studies recruiting: FIGHT-HF at the Cleveland Clinic (50 patients) and SCALE-PD in peritoneal dialysis (125 patients). Both started in autumn 2025. Public record
Health system pilot Geisinger, 12 months, about 200 patients, announced Aug 2023. No published result or renewal. Partner-stated
Revenue and customers None disclosed. The platform page cites SOC 2 Type 2 assessment and billing support, but names no payer or provider contract. Not found

What to watch

  • A first Form D. Six years without one suggests it will keep raising outside Regulation D.
  • Terms attached to the Terumo Medical position, which no public document describes.
  • FIGHT-HF results, primary completion estimated March 2026, and SCALE-PD, estimated June 2026.
  • Any named commercial contract, which would be the first revenue signal in the public record.

The Bodyport story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Bristle Health: Shared investor: Initialized. A saliva test that sequences the whole oral microbiome and sells the answer to consumers and to dental practices
  • Stellar Sleep: Shared investor: Initialized. A subscription app delivering the psychology sleep clinicians use, built by two people who could not get an appointment
  • Data Driven Bioscience: Shared investor: Initialized. A Durham company that sells hospital laboratories a kit for reading a tumor’s DNA and RNA in a single preparation, on the sequencer the lab already owns
  • Mable: Shared investor: Initialized. A DNA guided migraine clinic that paired a cheek swab with telehealth prescribing

Sources

  1. Public recordSEC EDGAR full text search and company search, BodyportSEC · Sep 22, 2026
  2. Public recordFDA 510(k) K211585 and openFDA registration 3020885267FDA · Sep 22, 2026
  3. Public recordClinicalTrials.gov NCT07205120 and NCT07059962Recruiting · 2025 to 2026
  4. IndependentBodyport secures $11.2m to build a virtual cardiac clinicMassDevice · Aug 11, 2020
  5. IndependentBodyport raises $11.2M, collaborates with Brigham and Women’sMedCity News · Aug 11, 2020
  6. InvestorBodyport Collects Lifesaving DataView from Initialized · Aug 11, 2020
  7. CompanyBodyport Raises $11.2 Million in Series A FundingBusiness Wire · Aug 11, 2020
  8. CompanyBoard appointment releases, Apr 2021 and Jun 2022Bodyport
  9. CompanyResearch and press boilerplate, Oct 2025 to Jan 2026Bodyport · accessed Sep 22, 2026

Compiled from SEC, FDA and ClinicalTrials.gov public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; no such notice exists for this company, and offerings made under other exemptions are not captured by that record. Healthcare Venture Capital Fund holds no position in Bodyport. This page is not an offer to sell or a recommendation to buy any security.